Current Research Studies
Cancer – AINV18P1: Phase 1 Study of Palbociclib, A CDK 4/6 Inhibitor, in Combination with Chemotherapy in Children with Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Condition or Therapy:
B- or T-lineage Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Category:
What is the goal of this study?
The goal of this study is to determine the maximum dose of palbociclib given with re-induction chemotherapy in pediatric patients with relapsed B- or T-lineage ALL/LL.
Who can join the study?
This study might be a good fit for children and young adults who:
- Are between 12 months and 31 years old
- Have recurrent or refractory B- or T- lineage lymphoblastic leukemia and lymphoma
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or send us an email.
